ACS 2010
Recent articles
Uncharted territory
Drug companies have been curiously reluctant to dive into research on therapies for autism. The chief of Pfizer's new autism research unit explains why.
Uncharted territory
Drug companies have been curiously reluctant to dive into research on therapies for autism. The chief of Pfizer's new autism research unit explains why.
True blood
Early data suggest that it is possible to identify autism by looking at gene expression in the blood. But it’s going to take more work to prove it.
True blood
Early data suggest that it is possible to identify autism by looking at gene expression in the blood. But it’s going to take more work to prove it.
Database groups common concepts in autism tests
A searchable new database will greatly ease the task of comparing results from more than 25 diagnostic tests for autism, by creating clusters of the various symptoms measured.
Database groups common concepts in autism tests
A searchable new database will greatly ease the task of comparing results from more than 25 diagnostic tests for autism, by creating clusters of the various symptoms measured.
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.